The board of directors of Clinigen Group plc and the board of directors of Triley Bidco Limited Jan. 17 agreed the terms of an increased and final recommended all-cash offer for Clinigen by Bidco, a newly-incorporated company indirectly owned by the Triton Funds, pursuant to which Bidco will acquire the entire issued and to be issued ordinary share capital of Clinigen at a price of 925 pence in cash per Clinigen share

You need to subscribe for access to restricted content.

Subscribe